Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | BMC Cancer

Fig. 4

From: Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer

Fig. 4

Drug testing and molecular profiling reveal sensitivity and co-resistance networks in T-47D Tam2. a DSS differences of tamoxifen-resistant T-47D Tam2 vs parental cells reveal emerging sensitivities (above the dotted line) and co-resistances (below the dotted line) upon acquiring tamoxifen resistance. b Color legend of the drug target class. For visualization purposes, the drugs were colored according to their target class as indicated, and the coloring matched with their target genes. c Drugs with DSS difference >5. Positive values indicate sensitivity and negative co-resistance. d Matching of the drugs that the cells show acquired sensitivity or co-resistance towards with their specific target genes reveals molecular networks behind sensitivity and co-resistance in T-47D Tam2. Drugs without target genes in the networks are not displayed. Drug targets (colored) and upstream molecules (uncolored) are denoted as follows: ovals, molecules without genomic changes; rectangles with solid line, molecules with copy number deletions, high confidence (p < 0,05 and resistant/parental frequency >30 %) point mutations could not be connected to the network and are thus not displayed. Molecules that are connected with the ER signalling pathway are connected by a dark grey line to the boxed text “Estrogen Receptor Signalling”

Back to article page